RenovoRx and Imugene Collaborate to Utilize Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform for Oncolytic Virus Therapy Delivery
RenovoRx, a leading medical technology company, and Imugene, a biotechnology company specializing in immunotherapies, have announced a collaboration to utilize RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform for the delivery of oncolytic virus therapy. This partnership aims to enhance the effectiveness of cancer treatment by combining the targeted delivery capabilities of TAMP™ with Imugene’s innovative oncolytic virus therapies.
Oncolytic virus therapy is an emerging field in cancer treatment that utilizes viruses to selectively infect and destroy cancer cells while leaving healthy cells unharmed. This approach has shown promising results in various types of cancer, including melanoma, breast cancer, and lung cancer. However, one of the challenges in oncolytic virus therapy is ensuring efficient and targeted delivery of the viruses to the tumor site.
This is where RenovoRx’s TAMP™ platform comes into play. TAMP™ is a minimally invasive procedure that allows for precise delivery of therapeutic agents directly to the tumor site through the arterial blood supply. It involves the use of a dual-balloon catheter system that isolates the target tissue and creates a temporary blood flow occlusion, enabling higher concentrations of therapeutic agents to be delivered directly to the tumor.
By combining Imugene’s oncolytic virus therapies with RenovoRx’s TAMP™ platform, the collaboration aims to overcome the limitations of traditional systemic administration methods. Systemic administration often results in low concentrations of therapeutic agents reaching the tumor site, leading to suboptimal treatment outcomes. The targeted delivery enabled by TAMP™ can potentially enhance the efficacy of oncolytic virus therapy by ensuring higher concentrations of viruses reach the tumor, increasing their ability to infect and destroy cancer cells.
The collaboration between RenovoRx and Imugene holds significant promise for improving cancer treatment outcomes. By leveraging the strengths of both companies, they aim to develop a comprehensive solution that combines the power of oncolytic virus therapy with precise and targeted delivery. This approach has the potential to revolutionize cancer treatment by maximizing the therapeutic benefits while minimizing side effects.
Dr. John Lewin, CEO of RenovoRx, expressed his excitement about the collaboration, stating, “We are thrilled to partner with Imugene to explore the potential of combining our TAMP™ platform with their innovative oncolytic virus therapies. This collaboration represents a significant step forward in advancing cancer treatment and improving patient outcomes.”
Leslie Chong, CEO of Imugene, also shared her enthusiasm, saying, “The collaboration with RenovoRx aligns perfectly with our mission to develop novel immunotherapies that can make a meaningful difference in the lives of cancer patients. By utilizing their TAMP™ platform, we can enhance the delivery of our oncolytic virus therapies and potentially unlock new possibilities in cancer treatment.”
The collaboration between RenovoRx and Imugene highlights the importance of partnerships in advancing medical technology and improving patient care. By combining their expertise and resources, these companies are poised to make significant strides in the field of oncolytic virus therapy. As research and development continue, it is hoped that this collaboration will lead to more effective and targeted treatments for cancer patients worldwide.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.